8-K: InMed Pharmaceuticals Reports Positive Q1 Fiscal 2025 Results and Provides Business Update

InMed Pharmaceuticals announced its first quarter fiscal 2025 financial results, highlighting progress in its pharmaceutical programs and commercial operations, including a 40% revenue increase in its BayMedica business.

Summary

• InMed Pharmaceuticals reported its financial results for the first quarter of fiscal year 2025, which ended September 30, 2024.
• The company's Alzheimer's treatment candidate, INM-901, showed positive preclinical data, including statistically significant results in certain behavioral criteria.
• BayMedica, InMed's commercial business, generated $1.3 million in revenue, a 40% increase compared to $0.9 million in the same period last year.
• BayMedica also reported a net income of $0.3 million, representing 24% of sales, for the quarter.
• Research and development expenses decreased to $0.8 million from $1.3 million in the same quarter of the previous year, primarily due to reduced spending on external contractors and patent fees.
• The company's cash, cash equivalents, and short-term investments totaled $5.6 million as of September 30, 2024, down from $6.6 million at June 30, 2024.
• InMed expects its cash to be sufficient to fund operations through the end of the first quarter of calendar year 2025, depending on BayMedica's revenue and operating expenses.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong revenue growth in BayMedica and promising preclinical data for INM-901. However, the decrease in cash and the need for a reverse stock split temper the overall sentiment.

Positives

• The INM-901 Alzheimer's program showed promising preclinical results, including statistical significance in behavioral criteria.
• Oral administration of INM-901 achieved therapeutic levels in the brain, which is a positive development for drug delivery.
• BayMedica's revenue grew by 40% year-over-year, indicating strong commercial performance.
• BayMedica achieved a net income of $0.3 million, demonstrating profitability.
• The company is actively exploring strategic opportunities to enhance long-term shareholder value.

Negatives

• The company's cash position decreased from $6.6 million to $5.6 million during the quarter.
• Research and development expenses decreased, which may indicate a slowdown in some areas of development.
• The company implemented a reverse stock split to regain Nasdaq compliance, which can be viewed negatively by some investors.

Risks

• The company's cash reserves are expected to last only until the end of the first quarter of calendar year 2025, depending on revenue and expenses.
• The company's future success depends on the successful development and commercialization of its drug candidates.
• The company faces risks associated with the pharmaceutical industry, including regulatory hurdles and competition.
• The company's financial performance is dependent on the success of its BayMedica commercial business.

Future Outlook

The company expects its cash to be sufficient to fund its planned operating expenses and capital expenditure through to the end of the first quarter of calendar year 2025, depending on the level and timing of BayMedica commercial revenues, as well as the level and timing of operating expenses. The company also anticipates further data read-out for INM-901 in calendar 4Q 2024 and increased R&D spending in calendar year 2025.

Management Comments

• Eric A. Adams, InMed Chief Executive Officer, stated that fiscal 2025 has commenced on a positive trajectory, with notable progress across pharmaceutical programs and commercial operations.
• Adams also mentioned that the company is encouraged by the promising data supporting the INM-901 program and the multiple potential mechanisms of action observed with this drug candidate.
• Adams noted the company's commitment to maintaining its listing on a major exchange while actively exploring strategic opportunities to enhance long-term shareholder value.

Industry Context

The focus on neuroinflammation in Alzheimer's research aligns with InMed's research direction, indicating the company is addressing a relevant and evolving area of the pharmaceutical industry. The company's development of treatments for age-related macular degeneration also places it in a competitive space with other companies developing treatments for similar conditions.

Comparison to Industry Standards

• The 40% revenue growth in BayMedica is a strong result compared to many early-stage pharmaceutical companies, but it is important to note that this is a commercial business unit and not the core pharmaceutical development.
• The decrease in R&D spending may be a concern, as it could indicate a slowdown in the development of the company's drug candidates. However, the company has stated that R&D spending is expected to increase in calendar year 2025.
• The company's cash position of $5.6 million is relatively low for a pharmaceutical company with multiple drug candidates in development, and the company's cash runway is only until the end of the first quarter of calendar year 2025.

Stakeholder Impact

• Shareholders may be impacted by the reverse stock split and the company's cash position.
• Employees may be impacted by changes in research and development spending.
• Customers of BayMedica may benefit from the company's continued growth and profitability.
• Suppliers may be impacted by changes in the company's spending.

Next Steps

• The company will conduct further molecular analyses from the recently completed long-term preclinical dosing study for INM-901.
• Data read-out from the INM-901 study is anticipated in calendar 4Q 2024.
• Additional in vivo preclinical dose ranging studies for INM-089 will be conducted.
• Good Laboratory Practice (GLP) studies for INM-089 are set to commence.
• The company will continue to monitor expenses while advancing its pharmaceutical pipeline candidates.

Key Dates

Keywords

INM-901, Alzheimer's, INM-089, AMD, BayMedica, Pharmaceuticals, Drug Development, Preclinical Studies, Revenue, Net Income, Reverse Stock Split